Archimedes to develop novel intranasal granisetron product

Archimedes will be responsible for developing the formulation of a novel intranasal granisetron product under a new agreement.

It has teamed up with Almac to work on the medication, which is hoped will provide rapid, well-tolerated and convenient therapy for patients suffering from chemotherapy-induced nausea and vomiting. It uses Archimedes’ ChiSys delivery technology.

Galen, a company that looks after Almac’s sales and marketing, will receive a number of royalties and milestone payments throughout the progression and launch of the item as part of the deal.

Vice-president of Archimedes’ research and development division Dr Alan Smith explained pre-clinical data from the firm’s intranasal granisetron product has so far been promising.

“[The compound] holds wide commercial potential by delivering an effective, easily administered and fast-acting treatment for patients who are already severely ill,” he stated.

Dr Iain James, vice-president of Almac’s Biology department, added the company is looking forward to working with Archimedes on the project.

Last month, the latter firm announced its clinical results from a phase III study showed NasalFent could be an effective therapy to help alleviate breakthrough cancer pain.